| Record ID | marc_columbia/Columbia-extract-20221130-031.mrc:122490319:3851 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-031.mrc:122490319:3851?format=raw |
LEADER: 03851cam a2200685Ia 4500
001 15092085
005 20220528232133.0
006 m o d
007 cr cnu---unuuu
008 130805t20132013enka ob 001 0 eng d
010 $z 2013006115
035 $a(OCoLC)ocn855022848
035 $a(NNC)15092085
040 $aN$T$beng$epn$cN$T$dE7B$dIDEBK$dCDX$dUMC$dOCLCF$dOCLCO$dCCO$dOCLCQ$dDEBSZ$dYDXCP$dEBLCP$dOCLCO$dOH1$dOCLCQ$dOCLCO$dAZK$dOCLCQ$dYDX$dOCLCO$dOCLCA$dMOR$dOCLCO$dVGM$dOCLCQ$dOCLCA$dNRAMU$dOCLCA$dINT$dOCLCQ$dWYU$dTKN$dUKAHL$dOCLCQ$dBOL$dK6U$dOCLCO
019 $a855504824$a961635064$a962647777$a988482232$a1045506018$a1114348876
020 $a9781409448280$q(electronic bk.)
020 $a1409448282$q(electronic bk.)
020 $a9781299925113
020 $a1299925111
020 $z9781409448273$q(print)
020 $z9781472403643$q(epub)
035 $a(OCoLC)855022848$z(OCoLC)855504824$z(OCoLC)961635064$z(OCoLC)962647777$z(OCoLC)988482232$z(OCoLC)1045506018$z(OCoLC)1114348876
050 4 $aHD9665.5$b.A574 2013eb
060 4 $a2013 K-465
060 4 $aQV 736.1
072 7 $aBUS$x070130$2bisacsh
082 04 $a338.4/76151$223
049 $aZCUA
100 1 $aAnsell, John,$d1947-
245 10 $aTransforming big pharma :$bassessing the strategic alternatives /$cJohn Ansell.
264 1 $aFarnham, Surrey :$bGower Publishing Limited,$c[2013]
264 4 $c©2013
300 $a1 online resource :$billustrations
336 $atext$btxt$2rdacontent
337 $acomputer$bc$2rdamedia
338 $aonline resource$bcr$2rdacarrier
340 $gpolychrome.$2rdacc$0http://rdaregistry.info/termList/RDAColourContent/1003
347 $atext file$2rdaft$0http://rdaregistry.info/termList/fileType/1002
504 $aIncludes bibliographical references and index.
588 0 $aPrint version record.
505 0 $apt. I. How pharma differs and why this is important -- pt. II. Assessing management concepts for the pharmaceutical industry -- pt. III. Big pharma's strategic options -- pt. IV. Where will new products come from? -- pt. V. Prospects for new products -- pt. VI. Getting a true fix on prospects -- pt. VII. Conclusions and summary.
520 $aTransforming Big Pharma addresses critically how strategy works in the pharmaceutical industry. John Ansell assesses the wide range of alternative strategies big pharma has been attempting in order to make up the shortfall in revenues stemming from the long-standing failure to develop sufficient new products. He shows that there is sound evidence to expect the recent upturn in the number of new products reaching the market to go on to greater heights. Whilst diversification may have some value as a stopgap, big pharma companies risk squandering their resources in directions that can only make.
650 0 $aPharmaceutical industry$xManagement.
650 0 $aStrategic planning.
650 12 $aDrug Industry$xeconomics
650 12 $aDrug Industry$xtrends
650 22 $aPharmacy Administration
650 6 $aIndustrie pharmaceutique$xGestion.
650 6 $aPlanification stratégique.
650 7 $aBUSINESS & ECONOMICS$xIndustries$xPharmaceutical & Biotechnology.$2bisacsh
650 7 $aPharmaceutical industry$xManagement.$2fast$0(OCoLC)fst01060159
650 7 $aStrategic planning.$2fast$0(OCoLC)fst01134371
650 7 $aPharmazeutische Industrie$2gnd
650 7 $aGroßbetrieb$2gnd
650 7 $aStrategisches Management$2gnd
655 0 $aElectronic books.
655 4 $aElectronic books.
776 08 $iPrint version:$aAnsell, John, 1947-$tTransforming big pharma.$dFarnham, Surrey : Gower Publishing Limited, [2013]$z9781409448273$w(DLC) 2013006115$w(OCoLC)828682598
856 40 $uhttp://www.columbia.edu/cgi-bin/cul/resolve?clio15092085$zTaylor & Francis eBooks
852 8 $blweb$hEBOOKS